SequelSEC

VivoSim Labs, INC. VIVS

Biological Products, (No Diagnostic Substances) · CIK 0001497253 · Fiscal year ends 0331

Revenue
$112.00K
Fiscal year ended 2026-06-30
Operating income
-$11.33M
Fiscal year ended 2026-06-30
Free cash flow
-$10.12M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$7.54MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-09-30
Float per share$2.16Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue57.5×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-09-30, not today, and each multiple below it uses the figures for the fiscal year ending 2026-03-31 — the year that filing covered.

How this compares in its industry

Percentile among the Biological Products, (No Diagnostic Substances) filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
CapEx / revenue0.0%0th
Gross margin100.0%98th
Net margin-10567.2%14th
FCF margin-8264.9%15th
Operating margin-8768.7%16th
R&D / revenue3197.7%78th
Current ratio2.38x30th
Revenue YoY growth-9.0%38th

VivoSim Labs, INC. (VIVS) reported revenue of $112.00K and net income of -$12.34M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from VivoSim Labs, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

VivoSim Labs, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$112.00K
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$11.33M
Net income-$12.34M
Research & development$4.32M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expense$5.00K
Diluted EPSUnavailable
Selling, general & administrative$7.12M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

VivoSim Labs, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$1.67M
Total assets$3.85M
Current assets$3.23M
Total liabilities$6.19M
Current liabilities$1.89M
Total equity incl. NCI-$2.35M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivable$29.00K
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$621.00K

Cash flow

VivoSim Labs, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$10.10M
Capital expenditures$23.00K
Investing cash flow$71.00K
Financing cash flow$2.64M
Net change in cash-$7.38M
Stock-based compensationUnavailable
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$194.00K

Derived

VivoSim Labs, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$10.12M
Gross marginUnavailable
Operating margin-10117.0%
FCF margin-9038.4%
SBC / revenueUnavailable
Current ratio1.70x
Revenue YoY growth-21.1%
Net margin-11016.1%
R&D / revenue3857.1%
CapEx / revenue20.5%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open VIVS in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-12View SEC filing
10-K · Filed 2026-07-14View SEC filing
10-Q · Filed 2026-02-11View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-K · Filed 2025-06-05View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.